Abeona Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$12.9M
Industry:Biotech
Founded:2015
Lead Investor(s):Jefferies LLC
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Abeona Therapeutics's estimated revenue is currently $5.3M per year.
  • Abeona Therapeutics received $92.0M in venture funding in October 2017.
  • Abeona Therapeutics's estimated revenue per employee is $57419
  • Abeona Therapeutics's total funding is $12.9M.

Employee Data

  • Abeona Therapeutics has 93 Employees.
  • Abeona Therapeutics grew their employee count by 45% last year.
  • Abeona Therapeutics currently has 1 job openings.

Executive Contacts

NameTitle
James BircherSVP Quality and Technical Operations
Aleixo SantiagoDirector
Scott SantiamoDirector Corporate Communications
Jaime FensterlAssociate Director, Program Management
Andre'a Andre'a LuccaVice President, Communications & Operations
Adam DavisDirector of Manufacturing
Magdalena TyrpienDirector, Corporate Strategy
Carolyn OdomAssociate Director, Program Management
Mark AlvinoDirector
Christine SilversteinChief Financial Officer

What Is Abeona Therapeutics?

Abeona Therapeutics Inc.(NASDAQ: $ABEO)is a leading clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

93

Number of Employees

$5.3M

Revenue (est)

1

Current Jobs

45%

Employee Growth %

$12.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
North Central B...
$38.6M2665%
Progenics Pharm...
$18.8M12915%
Sartorius Stedi...
$15.7M10826%
Outlook Therape...
$6.4M44100%
TG Therapeutics
$0.2M10219%
Prevail Therape...
$7.9M5596%
Trudeau Institu...
$11.3M7811%
Ichor Therapeut...
$5.3M3620%
SpringWorks The...
$8.5M59119%$103M
BioSpherix, Ltd...
$5.6M398%

Abeona Therapeutics News

09/03/2019 - Abeona Therapeutics Announces Strategic Review

NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in ...

09/03/2019 - Abeona Therapeutics (ABEO) Announces Strategic Review

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies ...

08/09/2019 - Abeona Therapeutics Reports Second Quarter 2019 Financial ...

NEW YORK and CLEVELAND, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in ...

Abeona Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-12-17$0.8MUndisclosedMultipleArticle
2014-12-02$3.6MUndisclosedMultipleArticle
2015-07-30$8.5MUndisclosedArticle
2017-10-18$92.0MUndisclosedJefferies LLCArticle

Abeona Therapeutics Executive Hires

DateNameTitleReference
2017-07-26Juan RuizChief Medical OfficerArticle
2018-04-03Carsten ThielChief Executive OfficerArticle
2018-10-22João SiffertHead of Research and Development and Chief Medical OfficerArticle
2019-02-12João SiffertCEOArticle

Abeona Therapeutics New Location/Offices

DateLocationReference
2018-06-06Columbus, OHArticle